Senthil Sundaram

Senthil Sundaram

Head of Business Development at INTERCEPT PHARMACEUTICALS INC

Update Profile
Location:
450 W. 15TH STREET SUITE 505, New York City, New York, United States
HQ Phone:
(646) 747-1000

General Information

Experience

Position, Healthcare Investment Banking Groups  - Lehman Brothers/Barclays

Chief Financial Officer  - NightstaRx Limited

Education

degrees  - Computer Engineering and Economics , Brown University

Affiliations

Co-Founder  - INGO Cucumber Waters

Recent News  

NightstaRx Ltd [BOSTON & LONDON] announced that Senthil Sundaram has joined the company as Chief Financial Officer.
Prior to joining Nightstar, Mr. Sundaram was the Vice President and Head of Business and Corporate Development at Intercept Pharmaceuticals, Inc. Prior to joining Intercept, Mr. Sundaram spent 13 years at Lehman Brothers/Barclays, Citigroup and Lazard.

Read More

Senthil Sundaram Chief Financial Officer
Mr. Sundaram was the Vice President and Head of Business and Corporate Development at Intercept Pharmaceuticals, Inc., where he was responsible for a wide range of activities including business development, strategy, financial analysis, investor relations and capital raising. While at Intercept, he was highly ranked on the Institutional Investor Magazine's survey for the Biotechnology All-America Executive Team. Prior to joining Intercept, Mr. Sundaram spent 13 years in the healthcare investment banking groups at Lehman Brothers/Barclays, Citigroup and Lazard. His transaction experience includes mergers & acquisitions, initial public offerings and other equity and debt financings in the biopharmaceuticals sector with an aggregate transaction value in excess of $115 billion. Mr. Sundaram is a graduate of Brown University, where he obtained degrees in Computer Engineering and Economics.

Read More

BOSTON - April 4, 2017 -- NightstaRx Ltd ("Nightstar"), a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, today announced that Senthil Sundaram has joined the company as Chief Financial Officer.
Mr. Sundaram brings over 17 years of investment banking and strategic operations experience and will lead Nightstar's corporate finance, corporate development and approach to broader strategic business relationships. In his new role, Mr. Sundaram will report directly to Nightstar's Chief Executive Officer, David Fellows, from the company's U.S. headquarters in Lexington, Mass. "We are delighted to have Senthil join the Nightstar team," said David Fellows. "Senthil comes to us after the recent initiation of the clinical trial for our second gene therapy candidate for X-linked retinitis pigmentosa, which has generated significant interest from ophthalmologists and patients. His depth of experience and leadership will be invaluable as we continue to build Nightstar into the leading company maintaining and restoring sight in patients with inherited retinal dystrophies." "Nightstar is a unique combination of strong science, world-class researchers and stellar management," said Mr. Sundaram. "I have family and friends who have been impacted by debilitating ophthalmic disorders. The opportunity to work at a company that has the potential to significantly alter the course of progressive blindness with a single treatment is highly attractive. I am excited to join this leading gene therapy company and help in the effort to make Nightstar's therapies a reality for patients." Prior to joining Nightstar, Mr. Sundaram was the Vice President and Head of Business and Corporate Development at Intercept Pharmaceuticals, Inc., where he was responsible for a wide range of activities including business development, strategy, financial analysis, investor relations and capital raising. While at Intercept, he was highly ranked on the Institutional Investor Magazine's survey for the Biotechnology All-America Executive Team. Prior to joining Intercept, Mr. Sundaram spent 13 years in the healthcare investment banking groups at Lehman Brothers/Barclays, Citigroup and Lazard. His transaction experience includes mergers & acquisitions, initial public offerings and other equity and debt financings in the biopharmaceuticals sector with an aggregate transaction value in excess of $115 billion. Mr. Sundaram is a graduate of Brown University, where he obtained degrees in Computer Engineering and Economics.

Read More

Browse ZoomInfo’s Directories